Lilly CEO: Pharma will snub Boston

Eli Lilly CEO John Lechleiter isn't happy with new Massachusetts legislation governing the way drugmakers market their products to doctors: He's saying that the limits will hamper innovation and force companies to reconsider expanding in the state. Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.